Adamas Announces Positive Phase 3 Results for Treatment of Levodopa-induced Dyskinesia in Patients With PD


(December 23, 2015) - Adamas Pharmaceuticals, Inc. today announced that its Phase 3 EASE LID clinical trial evaluating the company’s investigational compound ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease met its primary endpoint. ” With these data in hand, we look forward to talking with the FDA about our planned NDA submission for ADS-5102” stated the Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc. Read more…

Click for a printer friendly version

Back to top